ECEZ Is On HIGH ALERT! Let’s get right to it… My HUGE New Breakout Play Is: ECEZ Wall Street is about to Show Major Interest in ECEZ. One of Wall Street’s Top Analysts issued an ultimate price target for ECEZ of $3.67. Symbol: ECEZ Co Name: Ecosciences Inc. Breakout Catalyst: (Analyst $3.67 Price Target) ECEZ Is On Immediate ALERT! About Ecosciences Inc. Ecosciences, Inc. focuses on building, acquiring and investing in businesses around ecological and life sciences. From waste water remediation to healthcare and more, Ecosciences Inc. is committed to building a better living environment for all people. ECEZ Operates In the Staggering $37 Billion Remediation Industry! This upstart American company has come up with a radical breakthrough that could cure a stubborn crisis that’s been crippling American industry for years. The breakthrough could rapidly reverse a decade’s long pollution burden on companies that it's liable to make fortunes for early, ground floor investors. In fact, that many uses for this breakthrough are so far reaching - global scale - that you may never again come across a young company with such enormous growth potential. Here is just one major crisis that EcoScience's (ECEZ) pioneering breakthrough could help cure. It could light up ECEZ's shares. Scientists call it the DEAD ZONE. According to Analyst Report ECEZ Could Hit $3.67 If It Becomes Americas First Large-Scale Pollution Killer. Every spring, a huge swath of watery death and destruction spreads across the Gulf of Mexico from Texas to Florida. It's called - the Dead Zone. That's not hyperbole! It's an annual aquatic tragedy... 5,000 to 8,000 square miles of the Gulf run out of oxygen in places where marine life most abundant. The dead zone is caused by the massive amount of pollution that flows into the Gulf from the 3,710-mile length of the Missouri and Mississippi Rivers. The scope is staggering. If this happened on land - where people noticed it would be like seeing every animal in New Jersey drop dead or un for its life. That would be huge news. Time Is Running Out for the Gulf - But Help Is On The Way! But don't think the crisis in the Gulf is unknown just because CNN and Fox reporters aren’t making noise about it. Nearly Half the U.S. sends its grease and pollution downriver to the Gulf of Mexico. Millions of business, governments, and citizens have been taxed with rules and regulations to try to stem the destruction. In cities, too, half of all sewage overflows come down to FOG-Fat, oil and grease blockages. There is FINALLY a real solution at hand, however. ECEZ has an answer that's cheap fast, and effective to. That’s why it's urgent that you make an immediate move on EcoScience Inc. (ECEZ), before words gets out. Time Is Moving Fast for ECEZ Investors, To! The problem with the deadly pollution flowing into the Gulf is that it originates from thousands of commercial seemingly harmless sources in the vast watershed that encompasses the Missouri and Mississippi rivers. Not to mention millions of homes. That’s why ECEZ could soon be worth hundreds of millions of dollars, because the whole Mississippi-Missouri watershed takes in about half the U.S. Because it’s not just pig farms, or industry that’s spoiling the rivers. It's everything from restaurant grease traps, retention ponds and septic tanks to a whole lot more. And, believe me I live with the dead zone problem. As a Floridian, I know every Gulf state Texas, Louisiana, Mississippi, Alabama understands that a solution is critical. These states are going to line up and empty the banks for a strong solution. I believe that EcoScience (ECEZ) is what they've been dreaming about. Because ECEZ's solution is as easy to implement and as simple as plunking a high-tech tablet or two into each source of pollution. According to Analyst Report ECEZ Won't Be an Under-$1 Stock Much Longer! Small Solutions Mean Massive Investment potential for You... Up to 16X Your Stake in the Long Run... ECEZ investors who are smart enough to spot this opportunity while ECEZ is still under $1... before it could soar... could stand to make a killing. Restaurant alone have thousands (as in $$$$) of reasons to hop on board. This is the moment when EcoScience Inc. (ECEZ) moves into action... when most people wont see a giant investment potential, or realize the multi-billion dollar remediation market ECEZ is setting out to capture. Young and Growing... 2,855% + Potential, But Only to Investors Who Move Fast We all want to see healthy ocean off the coast of America. We want our shrimp cocktails, to. But the real truth today is that investors like us are looking for winners, not causes. EcoSciences Inc. (ECEZ) is doing saintly work, but it's a heck of an opportunity. Right now while shares are under $1 you could load up without breaking the bank... that’s the potential to turn spare change into a small fortune. According to Analyst Report ECEZ's sales potential suggest that a $3.67 share price could be an easy target... That would turn a little over $5,000 investment into a $917,500 payday for you. Ratchet $10,000 into $1,835,000 win. I know this looks very astronomical, and it is very uncommon to see 5k turn into 900k But, what if it only does 1/10th of the target and hits .36 cents. At .36 cents…That would turn a little over $5,000 investment into a $90,000 payday for you. You would be very happy with that, who wouldn't... Really, do you want to miss this? You may not see another chance like this for years. I am urging all members to begin your research right away and let’s be ready to trade Friday morning as ECEZ looks like its setting up for a major breakout! Start Your Research Now! Begin your ECEZ research at the company's website by using this link ---> http://ecosciences.company/ Best Regards, The OTCtipReporter Team DON'T MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY The companies that are discussed on OTCtipReporter have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCtipReporter is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Nor are any of its officers, affiliates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTCtipReporter or mentioned herein. Affiliates, officers, directors and employees of OTCtipsReporter may have also bought or may buy shares of companies mentioned herein and may profit in the event those shares rise in value. OTCtipsReporter will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions. These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains "forward looking" statements within the meaning of Section-27(a) of the U.S. Securities Act-of-1933 and Section 21(e) of the U.S. Securities Exchange Act-of -934. Neither OTCtipsReporter, its officers, affiliates, or employees is a broker-dealer. The information on OTCtipsReporter, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as investment-advice, and does not constitute an offer to sell any securities, nor is it to be construed as a solicitation to purchase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains "forward-looking statements," within the meaning of Section-27A of the Securities Act-of-1933 and Section 21E of the Securities Exchange Act-of-1934. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Securities and Exchange Commission by the companies who are mentioned in this periodical. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein. More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at sec, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549. Buying and Selling of Shares OTCtipsReporter intends to sell its shares. OTCtipsReporter may sell its shares for less than target prices given in opinions. OTCtipsReporter affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value. OTCtipsReporter will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTCtipsReporter are not analysts and investing in securities such as the ones listed within are for high risk tolerant individuals only and not the general public. Whether you are an experienced investor or not you should always consult with a broker before purchasing or selling any securities viewed on OTCtipsReporter. If at any time you wish to be removed from our list simply unsubscribe in any of the previous emails sent to you. 17(B) DISCLAIMER OTCtipsReporter is owned and operated by LionsGate Ventures Inc.. LionsGate Ventures Inc. and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as "OTC" or "we" or "us" or "our). OTC electronically disseminates information (the "Information") on its website, in newsletters, featured reports, spam compliant double-opt in email communications or otherwise pertaining to Profiled Companies' (the "Issuer" or "Issuers" or "Profiled Company" or "Profiled Companies"), the securities of which are most frequently common stock shares quoted on the Over the Counter Bulletin Board ("OTCBB") or Pink Sheets. The Information is based on information received from Issuers, publicly available information, such as quarterly (with unaudited financial statements) and annual reports (with audited financial statements) filed with the Securities and Exchange Commission ("SEC"), quarterly and annual unaudited financial reports and Information and Disclosure Statements filed with the Pink Sheets, the Issuer's website and information obtained through search engines such as Yahoo Finance, Market Watch and Business Wire. We synthesize the Information from these informational sources for our Readers as a starting point for further inquiry into the Issuer and its securities. Because OTC receives compensation for OTC's dissemination of the Information (as disclosed in our Compensation Disclosure Section), including at times in the form of common stock shares (the "Shares"), OTC should not be considered to be an independent provider of the Information. OTC is not a research analyst, registered investment advisor or registered securities broker dealer and the Information should not be construed in any manner, shape or form as investment-advice, investment recommendations or opinions or viewpoints regarding the Profiled Company or its securities or as a solicitation to offer, purchase or sell the Profiled Company's securities. OTC does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Companies. Because the Information is presented on an "as is" basis, your use of the Information is at your own risk. OTC disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is accurate or reliable or free of errors. By reading the Information, the Reader hereby agrees to indemnify and hold OTC harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the Information. Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties as indicated by words such as "believes", "expects", "estimates", "may", "will" or "should" or "anticipates" or similar expressions. These forward looking statements may materially differ from the Issuer's actual operational and financial results or its actual achievements, claimed or otherwise. OTC does not undertake any responsibility whatsoever of these forward looking statements, nor any legal obligation whatsoever of updating the Information. The Information is presented only as a brief "snapshot" of the Profiled Company and should only be used, at most, and if at all, as a starting point for Readers to conduct a thorough investigation of the Profiled Company and its securities, to consult with their financial, legal or other advisor(s) and avail themselves of filings and information that may be accessed at sec or pink sheets or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (e) consulting investment guides at sec and finra pertaining to the risks of investing in penny stocks. In the end result, Readers must evaluate and bear all the risks associated with the Information, including reliance on its accuracy, completeness or usefulness. In all instances, the Reader should conduct further inquiry into the Profiled Company and its securities. The Profiled Companies are subject to possible risks, including but not limited to: (a) the Information pertains to penny stocks that are subject to the SEC's penny stock rules and commonly involve a high degree of risk that may result in the loss of some or all of an investment in the Profiled Company's securities; (b) the Issuer's penny stock may be thinly traded, which may lead to difficulties of selling its securities; (c) the SEC reporting issuer may be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or the Pink Sheet quoted company may be delinquent in its Pink Sheet reporting obligations as indicated by Pink Sheets New Service's posting a negative "sign" pertaining to the Issuer at pink sheets, as follows: (i) "Limited Information" for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) "Pink Sheets - No Information", which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) "Caveat Emptor", signifying "Buyer Beware" that there is a public interest concern associated with a company's illegal spam campaign, questionable stock promotion, known investigation of a company's fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions; (d) whether the Issuer is a development stage company with little or no operations, the securities of which should be considered extremely speculative for investment purposes; (e) OTC's selling of an Issuer's securities may cause its stock price to significantly decline, especially when such securities are thinly traded; (f) many companies that have their securities quoted on the OTCBB or Pink Sheets (as well as even Exchange listed companies) have been negatively affected by the current economic downturn and lack of adequate financing to meet their operational goals or expansion plans; (g) any percentage gain from the previous day close presented on our website at is not and should not be construed as any indication whatsoever of the future stock price of an Issuer's securities or its operational results; (h) many of the energy related and other Profiled Companies are subject to increasing environmental and other governmental regulations, which subjects them to significant costs and possible fines and liabilities for failure to comply with applicable state and federal statutes; (i) OTC may receive compensation in shares of the Issuer and it or its associates, affiliated entities, officers, directors or immediate family members may sell the Shares immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time; as a result, OTC's selling activities may cause significant volatility in the Issuer's stock price and/or significantly depress the Issuer's stock price; (j) OTC may buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which may cause significant volatility including drops in the price of the Issuer's stock price and/or significantly depress the Issuer's stock price; (k) future success of many OTCBB and Pink Sheet quoted Issuers is dependent upon receiving adequate financing or raising sufficient capital, which they may be unable to obtain; (l) there is an inherent and actual conflict of interest that exists between our Readers' interests and OTC's interests because OTC's owners, OTC: (i) receive the Shares as compensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including at the same time the Information is being disseminated or shortly thereafter or at any time; and (ii) buys and sells the Profiled Company's shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time; (m) we do not receive any direct verification from the Issuer regarding the Information; (n) a third party shareholder may have a potential or actual conflict of interest in paying OTC for the dissemination of the publication while still holding the Issuer's shares of common stock that he or she may sell after the third party shareholder has paid OTC with his or her shares; (o) the Information should not be interpreted in any shape, form or manner whatsoever as an indication of the Issuer's future stock price or future financial performance since, among other reasons, such "comparison" companies are listed on exchanges (i.e., the New York Stock Exchange) and trade at stock prices that are thousands of percent higher than the companies we profile; and (p) Readers may encounter difficulties determining what information contained in our publications is material or non-material making it all the more imperative that they conduct further investigation of the Profiled Company and its securities ; and (q) OTC hires third party Service Providers to electronically disseminate live news regarding the Issuer, information which we do not independently provide to the Service Provider or verify and upon which we have no control over. We pay cash consideration to the Service Providers; no securities compensation is paid to the Service Providers; and (r) our employees post messages on their individual message boards as a method of disseminating the Information on behalf of our Issuer clients which should never be used as a means of conducting analysis into the Issuer and should only be used as a starting point to obtain the names of pink sheet or OTC Bulletin Board. Please be advised that we have been compensated twenty thousand dollars cash by a non-affiliated third party to profile ECEZ for a one day investor awareness program. WE OWN NO SHARES. This message was sent to xxxxxx@gmail.com from: OTCtipReporter | info@OTCtipReporter.net | OTC | OTC | 4417 13th St. | | | Saint Cloud, , FL 34769 Manage Your Subscription: http://app.icontact.com/icp/mmail-mprofile.pl?r=109089066&l=21484&s=SUCY&m=899454&c=949039
